checkAd

     109  0 Kommentare GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab - Seite 3

    Lesen Sie auch


    The GeNeuro porteur Stock at the time of publication of the news with a raise of +0,31 % to 1,610EUR on Lang & Schwarz stock exchange (16. November 2022, 07:33 Uhr).

    Business Wire (engl.)
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von Business Wire (engl.)
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab - Seite 3 Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), …